---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-001763"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:35:59.054761+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lixte launches pre-clinical study of LB-100 to target pre-cancerous cells with NKI

## Summary
- New pre-clinical study tests if initiated cells with mutant RAS oncogene can be eliminated by LB-100.
- Collaboration with Netherlands Cancer Institute; led by Dr. René Bernards, NKI senior scientist and LIXTE board member.
- Study in animal models expands on LIXTE’s ongoing clinical trials for ovarian and colorectal cancers.
- LB-100 has shown patient tolerance with little toxicity in Phase 1 clinical trials.

## SEC filing metadata
- accession: 0001641172-25-001763
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000164117225001763/0001641172-25-001763-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000164117225001763/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-001763
- JSON: https://secwatch.observer/filing/0001641172-25-001763.json
- Plain text: https://secwatch.observer/filing/0001641172-25-001763.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.